TY - JOUR
T1 - Cross-reactive antibodies after sars-cov-2 infection and vaccination
AU - Amsterdam UMC COVID-19 S3/HCW study group
AU - Grobben, Marloes
AU - Van Der Straten, Karlijn
AU - Brouwer, Philip Jm
AU - Brinkkemper, Mitch
AU - Maisonnasse, Pauline
AU - Dereuddre-Bosquet, Nathalie
AU - Appelman, Brent
AU - Ayesha Lavell, A. H.
AU - Van Vught, Lonneke A.
AU - Burger, Judith A.
AU - Poniman, Meliawati
AU - Oomen, Melissa
AU - Eggink, Dirk
AU - Bijl, Tom Pl
AU - Van Willigen, Hugo Dg
AU - Wynberg, Elke
AU - Verkaik, Bas J.
AU - Figaroa, Orlane Ja
AU - De Vries, Peter J.
AU - Boertien, Tessel M.
AU - Bomers, Marije K.
AU - Sikkens, Jonne J.
AU - Le Grand, Roger
AU - De Jong, Menno D.
AU - Prins, Maria
AU - Chung, Amy W.
AU - De Bree, Godelieve J.
AU - Sanders, Rogier W.
AU - Van Gils, Marit J.
N1 - Funding Information: This work was supported by a Netherlands Organization for Scientific Research (NWO) Vici grant no. 91818627 (to RWS) and NWO ZonMw grant no. 10430022010023 (to MKB); by the Bill & Melinda Gates Foundation grants INV-002022, INV008818 (to RWS) and INV-024617 (to MJvG); by the Amsterdam UMC Corona Research Fund (to MKB); by an AMC Fellowship from Amsterdam UMC (to MJvG), and by an NHMRC career development fellowship (to AWC). The funders had no role in the study design, data collection, data analysis, data interpretation, or data reporting. Publisher Copyright: © Grobben et al.
PY - 2021/11/23
Y1 - 2021/11/23
N2 - Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11-to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2-to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.
AB - Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11-to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2-to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.
UR - http://www.scopus.com/inward/record.url?scp=85120882183&partnerID=8YFLogxK
U2 - https://doi.org/10.7554/eLife.70330
DO - https://doi.org/10.7554/eLife.70330
M3 - Article
C2 - 34812143
SN - 2050-084X
VL - 10
JO - eLife
JF - eLife
M1 - e70330
ER -